Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 5/20 | 0.45 |
| ▸ | ITGB7 | P26010 | 5/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3266156 | 1.00 | ITGA4 (0.45) | ITGA4ITGB7GAAMEN1KMT2A | |
| SCHEMBL28774120 | 0.84 | ITGA4 (0.47) | ITGA4ITGB7MEN1KMT2ALMNA | |
| SCHEMBL28774119 | 0.84 | ITGA4 (0.47) | ITGA4ITGB7MEN1KMT2ALMNA | |
| SCHEMBL27549589 | 0.83 | MEN1 (0.47) | GAAMEN1KMT2ALMNAMAPT | |
| SCHEMBL13398403 | 0.83 | MEN1 (0.47) | GAAMEN1KMT2ALMNAMAPT | |
| SCHEMBL9925979 | 0.83 | LMNA (0.50) | GAAMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL10086332 | 0.83 | LMNA (0.50) | GAAMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL28774123 | 0.83 | ITGA4 (0.47) | ITGA4ITGB7MEN1KMT2ALMNA | |
| SCHEMBL28774121 | 0.83 | ITGA4 (0.47) | ITGA4ITGB7MEN1KMT2ALMNA | |
| SCHEMBL6806963 | 0.82 | ITGA4 (0.59) | ITGA4ITGB7MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004642-B1 | BIFUNCTIONAL POLYAZAMACROCYCLIC CHELATING AGENTS | Nordion (Canada) Inc (CA) | 2017-07-26 | — | — | EP | disclosed |
| US-8518715-B2 | Bifunctional polyazamacrocyclic chelating agents | NORDION (CANADA) INC. (CA) | 2013-08-27 | — | — | US | disclosed |
| US-8198101-B2 | Bifunctional polyazamacrocyclic chelating agents | NORDION (CANADA) INC. (CA) | 2012-06-12 | — | — | US | disclosed |
| EP-1438299-B1 | BIFUNCTIONAL CHELATING AGENT FOR ACTINIUM | EUROP ECONOMIC COMMUNITY (BE) | 2010-06-02 | — | — | EP | disclosed |
| US-20090202521-A1 | Bifunctional Polyazamacrocyclic Chelating Agents | MDS (CANADA) INC. (CA) | 2009-08-13 | — | — | US | disclosed |
| WO-2007104135-A1 | BIFUNCTIONAL POLYAZAMACROCYCLIC CHELATING AGENTS | MDS (CANADA) INC. (CA) | 2007-09-20 | — | — | WO | disclosed |
| US-7132513-B2 | Bifunctional chelating agent | EUROPEAN COMMUNITY (BE) | 2006-11-07 | — | — | US | disclosed |
| US-7045606-B2 | Chelate compound containing ligand with steroids, enzymes, hapten and antibodies | EUROPEAN COMMUNITY (BE) | 2006-05-16 | — | — | US | disclosed |
| EP-0770610-B1 | Biospecific binding reactants labelled with luminescent lanthanide chelates and their use | WALLAC OY (FI) | 2005-07-06 | — | — | EP | disclosed |
| US-20040242852-A1 | Bifunctional chelating agent for actinium | EUROPEAN COMMUNITY (BE) | 2004-12-02 | — | — | US | disclosed |
| EP-1438299-A1 | BIFUNCTIONAL CHELATING AGENT FOR ACTINIUM | EUROPEAN COMMUNITY (BE) | 2004-07-21 | — | — | EP | disclosed |
| WO-2003024940-A1 | BIFUNCTIONAL CHELATING AGENT FOR ACTINIUM | EUROPEAN COMMUNITY (BE) | 2003-03-27 | — | — | WO | disclosed |
| US-20030027302-A1 | Bifunctional chelating agent | INSERM INSTITUT NATIOANL DE LA SANTE ET DE LA REOHERCHE MEDICALE (FR) | 2003-02-06 | — | — | US | disclosed |
| EP-1263741-A1 | BIFUNCTIONAL CHELATING AGENT | EUROPEAN COMMUNITY (BE) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001068618-A1 | BIFUNCTIONAL CHELATING AGENT | EUROPEAN COMMUNITY (BE) | 2001-09-20 | — | — | WO | disclosed |
| US-5859215-A | IMMUNOASSAY; DNA HYBRID ANALYSIS; COMPLEXING; MEDICAL DIAGNOSIS | WALLAC OY (FI) | 1999-01-12 | — | — | US | disclosed |
| EP-0770610-A1 | Biospecific binding reactants labelled with luminescent lanthanide chelates and their use | WALLAC OY (FI) | 1997-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090202521-A1 | Bifunctional Polyazamacrocyclic Chelating Agents | LPXN, FCGRT, POLQ | ITGA4 2423/4885ITGB7 1718/4885GAA 49/4885 |
| US-20030027302-A1 | Bifunctional chelating agent | H1-2, H1-0, H1-5 | ITGA4 2487/4885ITGB7 2947/4885GAA 2121/4885 |
| US-20040242852-A1 | Bifunctional chelating agent for actinium | SHBG, H1-5, CXXC5 | ITGA4 2102/4885ITGB7 2535/4885GAA 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.